Psyence Group has confirmed that it has exported purified pharmaceutical-grade psilocybin mushroom extract to its Contract Development & Manufacturing Organisation (CDMO) partner in the UK.
Psyence’s pharmaceutical psilocybin extract will be used by the CDMO to develop standardised pharmaceutical-grade psilocybin and psilocin extracts. The extracts will be formulated into a final product for regulatory approval internationally.
The product was exported from Psyence’s federally licensed ISO22000-certified production facility in Southern Africa, which is licensed to cultivate, extract and export psilocybin mushrooms for the legal, global medical market and commercial medical research market.
Psyence has partnered with a highly experienced Current Good Manufacturing Practice (CGMP) compliant full-lifecycle pharmaceutical services company, which is a trusted partner to the world’s most innovative biotech companies and leading pharmaceutical companies.
The CDMO partnership aligns with Psyence Group’s pharmaceutical product development and intellectual property strategy.
CEO of Psyence, Dr Neil Maresky, commented: “We are incredibly proud to be one of the first companies to successfully export our pharmaceutical grade psilocybin into the UK having recently concluding exports to Portugal and Canada.
“The UK has the potential to be a leader in psychedelics research and ensuring a supply of pharmaceutical grade psilocybin for future research and clinical trials in this market will be critical to achieving this.”
“Our on-site laboratory provides us with the ability to produce pharma grade psilocybin mushroom and extract for the legal psilocybin research markets globally,” says Tony Budden, Psyence Chief Strategy Officer.
“The systems and processes we have fine-tuned ensure that we were able to meet the UK’s stringent import requirements for this product. By concluding another successful export, we believe we are on track to become a preferred global supply partner for research markets worldwide.”
